Repression of ferritin expression increases the labile iron pool, oxidative stress, and short-term growth of human erythroleukemia cells

Blood

Volumn 97, Issue 9, 2001, Pages 2863-2871

  Kakhlon, Or ^a   Gruenbaum, Yosef ^a   Cabantchik, Zvi Loav ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; FERRITIN; IRON; PROTEIN SUBUNIT; PROTEINASE INHIBITOR; REACTIVE OXYGEN METABOLITE;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ERYTHROLEUKEMIA; HUMAN; HUMAN CELL; LYSOSOME; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

EID: 0035353194     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.9.2863     Document Type: Article

References (57)

1. Breuer W, Epsztejn S, Cabantchik ZI. Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron, II. J Biol Chem. 1995;270:24209-24215.
2. Epsztejn S, Kakhlon O, Glickstein H, Breuer W, Cabantchik I. Fluorescence analysis of the labile iron pool of mammalian cells. Anal Biochem. 1997;248:31-40.
3. Epsztejn S, Glickstein H, Picard V, et al. H-ferritin subunit overexpression in erythroid cells reduces the oxidative stress responses and induces multidrug resistance properties. Blood. 1999;94:1-12.
4. Picard V, Epsztejn S, Santambrogio P, Cabantchik ZI, Beaumont C. Role of ferritin in the control of the labile iron pool in murine erythroleukemia cells. J Biol Chem. 1998;273:15382-15386.
5. Balla J, Jacob HS, Balla G, Nath K, Eaton JW, Vercellotti GM. Endothelial-cell heme uptake from heme-proteins: induction of sensitization and desensitization to oxidant damage. Proc Natl Acad Sci U S A. 1993;90:9285-9289.
6. Cairo G, Tacchini L, Pogliaghi G, Anzon E, Tomasi A, Bernelli-Zarzera A. Induction of ferritin synthesis by oxidative stress: transcriptional and post-transcriptional regulation by expansion of the "free" iron pool. J Biol Chem. 1995;270:700-703.
7. Cozzi A, Corsi B, Levi S, Santambrogio P, Albertini A, Arosio P. Overexpression of wild type and mutated human ferritin H-chain in HeLa cells: in vivo role of ferritin ferroxidase activity. J Biol Chem. 2000;275:25122-25129.
8. Corsi B, Perrone F, Bourgeois M, et al. Transient overexpression of human H- and L-ferritin chains in COS cells. Biochem J. 1998;330:315-320.
9. Hudson AJ, Andrews SC, Hawkins C, et al. Overproduction, purification and characterization of the Esscherichia coli ferritin. Eur J Biochem. 1993;218:985-995.
10. Bevilacqua MA, Faniello MC, Russo T, Cimino F, Costanzo F. P/CAF/p300 complex binds the promoter for the heavy subunit of ferritin and contributes to its tissue-specific expression. Biochem J. 1998;335:521-525.
11. Tsuji Y, Kwak E, Saika T, Torti SV, Torti FM. Preferential repression of the hours subunit of ferritin by adenovirus E1A in NIH-3T3 mouse fibroblasts. J Biol Chem. 1993;268:7270-7275.
12. Tsuji Y, Akebi N, Lam TK, Nakabeppu Y, Torti SV, Torti FM. FER-1, an enhancer of the ferritin hours gene and a target of E1A-mediated transcriptional repression. Mol Cell Biol. 1995;15:5152-5164.
13. Tsuji Y, Moran E,Torti SV,Torti FM. Transcriptional regulation of the mouse ferritin hours gene: involvement of p300/CBP adaptor proteins in FER-1 enhancer activity. J Biol Chem. 1999;274:7501-7507.
14. Fuhrmann G, Rosenberger G, Grusch M, Klein N, Hofmann J, Krupitza G. The MYC dualism in growth and death. Mutat Res. 1999;437:205-217.
15. Wu KJ, Polack A, Dalla Favera R. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. Science. 1999;283:676-679.
16. Bevilacqua MA, Faniello MC, Quaresima B, et al. A common mechanism underlying the E1A repression and the cAMP stimulation of the hours ferritin transcription. J Biol Chem. 1997;272:20736-20741.
17. Modjtahedi N, Frebourg T, Fossar N, Lavialle C, Cremisi C, Brison O. Increased expression of cytokeratin and ferritin-H genes in tumorigenic clones of the SW 613-S human colon carcinoma cell line. Exp Cell Res. 1992;201:74-82.
18. Calabretta B, Skorski T, Ratajczak MZ, Gewirtz AM. Antisense strategies in the treatment of leukemias. Semin Oncol. 1996;23:78-87.
19. Gewirtz AM. Oligodeoxynucleotide-based therapeutics for human leukemias. Stem Cells. 1993;11(suppl 3):96-103.
20. Lin F, Girotti AW. Hemin-enhanced resistance of human leukemia cells to oxidative killing: antisense determination of ferritin involvement. Arch Biochem Biophys. 1998;352:51-58.
21. Breuer W, Greenberg E, Cabantchik ZI. Newly delivered transferrin iron and oxidative cell injury. FEBS Lett. 1997;403:213-219.
22. Levine RL, Williams JA, Stadtman ER, Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol. 1994;233:346-357.
23. Slotki IN, Breuer WV, Greger R, Cabantchik ZI. Long-term cAMP activation of Na(+)-K(+)-2Cl-cotransporter activity in HT-29 human adenocarcinoma cells. Am J Physiol. 1993;264:C857-C865.
24. Rittling SR, Woodworth RC. The synthesis and turnover of ferritin in rat L-6 cells: rates and response to iron, actinomycin D, and desferrioxamine. J Biol Chem. 1984;259:5561-5566.
25. Picard V, Renaudie F, Porcher C, Hentze MW, Grandchamp B, Beaumont C. Overexpression of the ferritin hours subunit in cultured erythroid cells changes the intracellular iron distribution. Blood. 1996;87:2057-2064.
26. Breuer W, Epsztejn S, Cabantchik ZI. Dynamics of the cytosolic chelatable iron pool of K562 cells. FEBS Lett. 1996;382:304-308.
27. Klausner RD, Rouault TA, Harford JB. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell. 1993;72:19-28.
28. Theil EC. Iron regulatory elements (IREs): a family of mRNA non-coding sequences. Biochem J. 1994;304:1-11.
29. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta. 1996;1275:161-203.
30. Konijn AM, Glickstein H, Vaisman B, Meyron HE, Slotki IN, Cabantchik ZI. The cellular labile iron pool and intracellular ferritin in K562 cells. Blood. 1999;94:2128-2134.
31. Radisky DC, Kaplan J. Iron in cytosolic ferritin can be recycled through lysosomal degradation in human fibroblasts. Biochem J. 1998;336:201-205.
32. Bomford A, Isaac J, Roberts S, Edwards A, Young S, Williams R. The effect of desferrioxamine on transferrin receptors, the cell cycle and growth rates of human leukaemic cells. Biochem J. 1986;236:243-249.
33. Cozzi A, Santambrogio P, Levi S, Arosio P. Iron detoxifying activity of ferritin: effects of hours and L human apoferritins on lipid peroxidation in vitro. FEBS Lett. 1990;277:119-122.
34. Weinberg ED. Iron depletion: a defense against intracellular infection and neoplasia. Life Sci. 1992;50:1289-1297.
35. Balla G, Jacob HS, Balla J, et al. Ferritin: a cytoprotective antioxidant stratagem of endothelium. J Biol Chem. 1992;267:18148-18153.
36. Konijn AM, Hershko C. Ferritin synthesis in inflammation, I: pathogenesis of impaired iron release. Br J Haematol. 1977;37:7-16.
37. Konijn AM. Iron metabolism in inflammation. In: Hershko C, ed. Baillere's Clinical Haematology: Clinical Disorders of Iron Metabolism. London: Baillere Tindall; 1994:829-850.
38. Elia G, Polla B, Rossi A, Santoro MG. Induction of ferritin and heat shock proteins by prostaglandin A1 in human monocytes: evidence for transcriptional and post-transcriptional regulation. Eur J Biochem. 1999;264:736-745.
39. Pham DQ, Winzerling JJ, Dodson MS, Law JH. Transcriptional control is relevant in the modulation of mosquito ferritin synthesis by iron. Eur J Biochem. 1999;266:236-240.
40. Anderson KP, Fox MC, Brown DV, Martin MJ, Azad RF. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob Agents Chemother. 1996;40:2004-2011.
41. Crooke ST, Bennett CF. Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol. 1996;36:107-129.
42. Mata JE, Bishop MR, Tarantolo SR, Angel CR, Swanson SA, Iversen PL. Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment. J Toxicol Clin Toxicol. 2000;38:383-387.
43. Hann HW, Stahlhut MW, Hann CL. Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology. 1990;11:566-569.
44. Kovar J, Franek F. Growth-stimulating effect of transferrin on a hybridoma cell line: relation to transferrin iron-transporting function. Exp Cell Res. 1989;182:358-369.
45. Kovar J. Insoluble iron compound is able to stimulate growth of cultured cells [letter]. In Vitro Cell Dev Biol. 1990;26:1026-1027.
46. Seligman PA, Kovar J, Schleicher RB, Gelfand EW. Transferrin-independent iron uptake supports B lymphocyte growth. Blood. 1991;78:1526-1531.
47. Kulp KS, Green SL, Vulliet PR. Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells. Exp Cell Res. 1996;229:60-68.
48. Pahl PM, Yan XD, Hodges YK, Rosenthal EA, Horwitz MA, Horwitz LD. An exochelin of Mycobacterium tuberculosis reversibly arrests growth of human vascular smooth muscle cells in vitro. J Biol Chem. 2000;275:17821-17826.
49. Chang HC, Lee TH, Chuang LY, Yen MH, Hung WC. Inhibitory effect of mimosine on proliferation of human lung cancer cells is mediated by multiple mechanisms. Cancer Lett. 1999;145:1-8.
50. Kyriakou D, Eliopoulos AG, Papadakis A, Alexandrakis M, Eliopoulos GD. Decreased expression of c-myc oncoprotein by peripheral blood mononuclear cells in thalassaemia patients receiving desferrioxamine. Eur J Haematol. 1998;60:21-27.
51. Kramer Stickland K, Edmonds A, Bair WB, Bowden GT. Inhibitory effects of deferoxamine on UVB-induced AP-1 transactivation. Carcinogenesis. 1999;20:2137-2142.
52. Bomford A, Conlon-Hollingshead C, Munro HN. Adaptive responses of rat tissue isoferritins to iron administration. J Biol Chem. 1981;256:948-955.
53. Melefors O, Hentze MW. Translational regulation by mRNA/protein interactions in eukaryotic cells: ferritin and beyond. Bioessays. 1993;15:85-90.
54. Hentze MW. Determinants and regulation of cytoplasmic mRNA stability in eukaryotic cells. Biochim Biophys Acta. 1991;1090:281-292.
55. Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 1991;51:3602-3609.
56. Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A. 1999;96:7797-7802.
57. Muller C, Bockhorn AG, Klusmeier S, et al. Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol. 1998;12:717-723.